United States - English - NLM (National Library of Medicine)

allergan, inc. - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug - linzess is indicated for the treatment of: • irritable bowel syndrome with constipation (ibs-c) in adults • chronic idiopathic constipation (cic) in adults • functional constipation (fc) in pediatric patients 6 to 17 years of age linzess is contraindicated in: - patients less than 2 years of age due to the risk of serious dehydration [see warnings and precautions ( 5.1 ), use in specific populations ( 8.4 )] . - patients with known or suspected mechanical gastrointestinal obstruction.  risk summary linaclotide and its active metabolite are negligibly absorbed systemically following oral administration [see clinical pharmacology ( 12.3 )] , and maternal use is not expected to result in fetal exposure to the drug. the available data on linzess use in pregnant women are not sufficient to inform any drug-associated risk for major birth defects and miscarriage. in animal developmental studies, no effects on embryo-fetal development were observed with oral administration of linaclotide in rats and rabbits during o

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug

European Union - English - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - linaclotide - irritable bowel syndrome - drugs for constipation - constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (ibs-c) in adults.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - linaclotide - oral capsule - 290microgram

Canada - English - Health Canada

abbvie corporation - linaclotide - capsule - 145mcg - linaclotide 145mcg - miscellaneous gi drugs

Canada - English - Health Canada

abbvie corporation - linaclotide - capsule - 290mcg - linaclotide 290mcg - miscellaneous gi drugs

Canada - English - Health Canada

abbvie corporation - linaclotide - capsule - 72mcg - linaclotide 72mcg - miscellaneous gi drugs

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - linaclotide - capsule - 290microgram

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - linaclotide, quantity: 0.29 mg - capsule, hard - excipient ingredients: calcium chloride dihydrate; hypromellose; microcrystalline cellulose; leucine; titanium dioxide; potable water; gelatin; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; shellac; sulfuric acid - constella is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (ibs-c) and ? chronic idiopathic constipation (cic) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.